Personalis, Inc. presenteert zich op Advances op het Immuno-Oncology Congress UK 2019
MENLO PARK, Californië (BUSINESS WIRE) – Personalis, Inc., een leider in geavanceerde genomica voor kanker, kondigde vandaag aan dat het bedrijf zich zal presenteren op Advances op het Immuno-Oncology Congres UK 2019 in Londen op 21 mei om 11:00 uur BST.
De presentatie, getiteld “Advancing Precision Oncology Biomarker Discovery with a Multi-dimensional Immunogenomics Platform,” zal Personalis’ nieuwe universele kankerimmunogenomics platform, ImmunoID NeXT™, introduceren. Naast een overzicht, zal de presentatie voorlopige gegevens uit een lopende studie introduceren waarin dit platform wordt gebruikt om IO-gerelateerde biomarkers en potentiële tumor ontsnappingsmechanismen te evalueren in een cohort van melanoompatiënten die behandeld worden met anti-PD-1 therapie.
Personalis, Inc. to Present at Advances in Immuno-Oncology Congress UK 2019
MENLO PARK, Calif.–(BUSINESS WIRE)– Personalis, Inc., a leader in advanced genomics for cancer, today announced that the company will present at Advances in Immuno-Oncology Congress UK 2019 in London on May 21st at 11:00 AM BST.
The presentation, entitled “Advancing Precision Oncology Biomarker Discovery with a Multi-dimensional Immunogenomics Platform,” will introduce Personalis’ new universal cancer immunogenomics platform, ImmunoID NeXT™. In addition to an overview, the presentation will introduce preliminary data from an ongoing study in which this platform is being used to evaluate IO-related biomarkers and potential tumor escape mechanisms in a cohort of melanoma patients treated with anti-PD-1 therapy.
ImmunoID NeXT™ is the first platform to provide comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The platform can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one. This maximizes the biological information that can be generated from a precious tumor specimen.
The presentation will be delivered by Robert Power, MS, Global Product Manager for Personalis.
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The company’s NeXT Platform™ is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single sample. The Personalis Clinical Laboratory is GxP-aligned as well as CLIA ’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).
View source version on businesswire.com: https://www.businesswire.com/news/home/20190520005195/en/
Contacts
Jennifer Havlek
pr@personalis.com
www.personalis.com
650-752-1300